One clinical trial assessed the approach of combining nivolumab or placebo with bevacizumab plus platinum-based chemotherapy for treatment of NSCLC patients without driver mutations in ALK, EGFR, or ROS1, evaluated the safety and effectiveness in the treatment plan [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.